Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer

NCT04381832 is registered in ClinicalTrials.gov with Arcus Biosciences, Inc. as lead sponsor.

NCT NCT04381832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04381832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Lead sponsor
Arcus Biosciences, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 7, 2020
Completion date
August 30, 2024
Enrollment
173 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

androgen-resistant prostatic neoplasms, castration resistant prostatic neoplasms, prostatic cancer, castration-resistant, prostatic neoplasms, castration-resistant